Hyperprolactinemia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Hyperprolactinemia is an early-stage landscape with 10 programs across 8 companies. The most active players are Glaxo Dba Glaxosmithkline, Pfizer, Korea Otsuka Pharmaceutical Co., Ltd.. 2 therapies are approved with 1 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Analysis
Modality Breakdown
75%
Small molecule
9 of 12 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 12 classified programs, each share of the total. Modality classified for 100% of 12 pipeline programs.
Analysis
Trial Status
10
clinical trials
Clinical Trials
Trial Activity
10 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)